Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first ever treatments for limb-girdle muscular dystrophy (LGMD) types 2D, 2B, 2E, 2L, and 2C based on research at Nationwide Children’s Hospital.